This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Citrate Pharmacokinetics and Regional Citrate Anticoagulation in CRRT

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2009 by Huashan Hospital.
Recruitment status was:  Recruiting
Shanghai Scientific and technology committe
Information provided by:
Huashan Hospital Identifier:
First received: July 28, 2009
Last updated: August 4, 2009
Last verified: August 2009
  1. To compare the differences of citrate pharmacokinetics in healthy individuals and critically ill patients as well as the influential factors.
  2. To validate a pharmacokinetic model which has been established in a formal paper.
  3. To create a safe and effective RCA-CRRT protocol.

Acute Kidney Failure With or Without: MODS Sepsis Hepatic Insufficiency

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Citrate Pharmacokinetics in Healthy Individuals and Critically Ill Patients and the Application of Regional Citrate Anticoagulation in Continuous Renal Replacement Therapy(RCA-CRRT).

Resource links provided by NLM:

Further study details as provided by Huashan Hospital:

Estimated Enrollment: 40
Study Start Date: March 2009
Estimated Study Completion Date: September 2011
Estimated Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
the subjects will be selected from a university teaching hospital in Shanghai, China.

Inclusion Criteria:

  • healthy individuals, none-pregnant
  • diagnosed with acute renal failure according to RIFLE criteria
  • ARF with hepatic insufficiency
  • ARF with MODS or sepsis
  • within informed consent

Exclusion Criteria:

  • used drugs with citrate within one week
  • infused with blood,plasma or platelet or undergone plasma exchange therapy within 48 hours
  • serious alkalosis with PH>7.55
  • serious lactic acidosis
  • not in resuscitation state
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00948558

Contact: Feng Ding, Professor 86-02152888135

Huashan hospital Recruiting
Shanghai, China, 200040
Contact: Feng Ding, doctor    81-02152888135   
Sponsors and Collaborators
Huashan Hospital
Shanghai Scientific and technology committe
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Feng Ding, Huashan Hospital Identifier: NCT00948558     History of Changes
Other Study ID Numbers: KY2009-108
Study First Received: July 28, 2009
Last Updated: August 4, 2009

Keywords provided by Huashan Hospital:
citrate anticoagulation
critically ill
acute kidney failure

Additional relevant MeSH terms:
Renal Insufficiency
Hepatic Insufficiency
Acute Kidney Injury
Kidney Diseases
Urologic Diseases
Liver Diseases
Digestive System Diseases
Citric Acid
Calcium Chelating Agents
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action processed this record on August 18, 2017